Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-center phase III persistence study of 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years
CTR20233877Phase 3Active
- Sponsor
- Zhifei Green Bamboo
- Start
- Dec 2023
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine in Pneumococcal pneumonia (PP), pneumococcal meningitis, Pneumococcal Otitis Media, pneumococcal bacteremia, sponsored by Zhifei Green Bamboo. Started Dec 2023; status: active.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
Pneumococcal pneumonia (PP)pneumococcal meningitisPneumococcal Otitis Mediapneumococcal bacteremia
Beyond the preview
Go deeper on CTR20233877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233877.